What is the market's earnings forecast for Nu Skin Enterprises next quarter?

What is Nu Skin Enterprises's latest dividend and current dividend yield?

What were the key takeaways from Nu Skin Enterprises's earnings call?

What were the key takeaways from Nu Skin Enterprises’s earnings call?

What does Nu Skin Enterprises do and what are its main business segments?

Did Nu Skin Enterprises beat or miss consensus estimates last quarter?

What guidance did Nu Skin Enterprises's management provide for the next earnings period?

What is Nu Skin Enterprises's gross profit margin?

- **Revenue and Profitability**: Q3 2025 revenue of $364 million (within guidance), EPS of 34 cents (high end of range), with gross margin improving to 70.5%.
- **Growth Drivers**: Latin America up 53% YoY; Prism IO device to reach 10,000+ units in Q4 2025; India pre-market opening with digital-first model.
- **Strategic Focus**: Shifting North America to intelligent wellness; RISE segment (LifeDNA) outperformed; cautious 2025 guidance reflects Prism IO and India launch risks.

**【Management Opening Remarks】**
- B.G. Hunt provided an overview of the call, emphasizing forward-looking statements and non-GAAP financial measures. The company highlighted its Q3 2025 results and strategic priorities for growth.

**【CEO Summary Section】**
- **Q3 2025 Financial Highlights**: Revenue of $364 million (within guidance), EPS of 34 cents (high end of guidance). Gross margin improved to 70.5%, driven by core business optimization.
- **Strategic Growth Drivers**: 
  - **Latin America Growth**: 53% YoY growth, showcasing success in emerging markets.
  - **Prism IO Launch**: A portable intelligent wellness device with 10,000+ units expected in Q4 2025, targeting 300,000+ subscribed customers by 2026.
  - **India Expansion**: Pre-market opening in Q4 2025, focusing on a digital-first model with localized products (e.g., SeraNu skincare line).
- **Segment Performance**: RISE segment (LifeDNA) exceeded expectations, while North America faced macroeconomic challenges but showed sequential improvement.

**【CFO Financial Commentary】**
- **Gross Margin Expansion**: 70.5% (vs. 70.1% YoY), driven by product mix optimization and cost control.
- **Cost Efficiency**: Selling expenses decreased to 35.8% of revenue (from 39% YoY), with core business selling expense at 41.7%.
- **Liquidity and Capital Allocation**: $252 million in cash, $20 million debt reduction, and $152.4 million remaining under share repurchase authorization.
- **Guidance Update**: Full-year 2025 revenue guidance narrowed to $1.48–$1.51 billion, with EPS of $3.15–$3.25.

**【Q&A Highlights】**
- **India Strategy**: Pre-market opening with a focus on digital infrastructure and localized products, aiming to learn and adapt to regional market dynamics.
- **North America Restructuring**: Shift from beauty to intelligent wellness with Prism IO, leveraging salesforce engagement and subscription-based models.
- **Southeast Asia Growth**: Sequential improvement driven by Pacific markets (e.g., Australia, New Zealand) and strong TR90 body transformation product performance.


NUS

NUS fundamentals

You can ask Aime